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SUMMARY
This review aims to provide an overview of complications 
associated with surgical treatment for urinary incontinence 
and pelvic organ prolapse relating to synthetic mesh, as well 
as review the new International Urogynecologic Association 
(IUGA)/ International Continence Society (ICS) classiﬁcation 
of complications for insertion of prosthesis or grafts in 
female pelvic ﬂoor surgery and the recent Food and Drug 
Administration (FDA) notiﬁcations. 
Key words: Urinary incontinence, pelvic organ prolapse, 
surgical treatment.
INTRODUCCIÓN
A multitude of surgical procedures have been described and modiﬁed 
in hope of attaining a durable cure for stress urinary incontinence (SUI) 
and pelvic organ prolapse (POP).  These surgeries were traditionally 
performed using the patient’s native tissues.  In an effort to decrease 
morbidity, improve surgical outcomes and minimize the complexity 
of these operations, an increasing number of repairs using synthetic 
mesh and biomaterials from cadaveric or xenograft tissue have been 
employed.  This review aims to provide an overview of complications 
associated with surgical treatment for urinary incontinence and pelvic 
organ prolapse relating to synthetic mesh, as well as review the 
new International Urogynecologic Association (IUGA)/ International 
Continence Society (ICS) classiﬁcation of complications for insertion of 
prosthesis or grafts in female pelvic ﬂoor surgery and the recent Food 
and Drug Administration (FDA) notiﬁcations. 
MESH IN SUI
Synthetic mesh has been used in the treatment of stress urinary incontinence 
with a wide variety of retropubic midurethral slings (MUS), transobturator 
MUS and single incision mini-slings. Success rates are estimated at 51 to 
99% for retropubic and transobturator slings (1-3).  Single incision mini-
slings have demonstrated lower success rates so far.  Success rates range 
from 31 to 91.9% (4, 5). Although extremely low rates of bowel injury, 
vascular injuries and death have been reported in the literature with the 
retropubic MUS, some surgeons prefer to use transobturator MUS to avoid 
these devastating complications and reduce the risk of bladder injury (3, 6, 
7).  Similarly, the mini-sling was devised as a less invasive procedure that 
could be performed safely in an ofﬁce setting.  Despite these technological 
advancements, placement of synthetic mesh for the treatment of stress 
urinary incontinence may result in both minor and serious complications. 
Lower urinary tract symptoms may be exacerbated with worsened or de 
novo urgency and urge incontinence in 11-28% (8-10).  MUS placement 
focuses on tension-free positioning but ways of achieving a tension-free 
placement is not standardized and difﬁcult to assess intraoperatively (11). 
Bladder outlet obstruction and/or voiding dysfunction can result from 
tension at time of sling placement but also from tissue contraction and 
ﬁbrosis in response to secondary scarring. Mesh complications can also 
include vaginal extrusion with related symptoms of vaginal bleeding, 
vaginal discharge or pain with intercourse for the patient or their partner 
(hispareunia) (12). Erosion into the urinary tract most commonly involve 
the bladder and/or urethra presenting with urinary frequency, urgency, 
dysuria, recurrent urinary tract infections or calculi.  Although persistent 
groin and medial thigh pain have been reported following transobturator 
MUS, transient pain is fortunately more common occurring in 5-31% 
(13-16). Pelvic pain and dyspareunia have been reported in up to 24% 
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following MUS, and can be a most distressing and potentially irreversible 
complication to rectify (17, 18). 
MESH IN POP
Mesh use for abdominal sacrocolpopexy dates back to 1962 (19) and 
is well established through long-term data (20, 21).  On the other 
hand, transvaginal repairs with either self-fashioned prolene mesh or 
commercial mesh kits are very controversial.  Mesh for anterior repair 
may improve anatomic outcomes but has not demonstrated a clear 
beneﬁt regarding quality of life and patient satisfaction in a recent 
meta-analysis (21, 22). Efﬁcacy of mesh repairs for vault repair and 
posterior repair has not been demonstrated, with low level evidence 
and short term studies (21, 22).  Most frequently cited complications 
are vaginal extrusion and exposure ranging from 5.8 to 20% (22, 
23)  De novo dyspareunia and pelvic pain is also a signiﬁcant concern 
reported in 1 to 69% (24).  Pain seems to be related to the amount 
of implanted mesh and likely partially attributable to mesh contraction 
(23). Fistulae may involve the urinary tract and/ or colo-rectal tract 
requiring aggressive intervention. (See Figure1.) Recurrent prolapse, 
infection, neuromuscular impairment, vaginal shrinkage, psychological 
problems and death have been reported complications associated with 
mesh for transvaginal POP repair (21).
FDA NOTIFICATIONS
The FDA released a Public Health Notiﬁcation in October 2008 in 
response to complications associated with urogynecologic use of 
surgical mesh (25).  The FDA conducted a search of the adverse events 
in Manufacturer’s and User Device Experience (MAUDE) database, 
revealing 3,979 cases from January 2005 to December 2010 with 
a 5 fold increase in reports of adverse events in POP repairs from 
January 2008 to December 2010 (21).  An “Update on the Serious 
Complications Associated with Transvaginal Placement of Surgical Mesh 
for Pelvic Organ Prolapse” was issued by the FDA in July 2011. Unlike 
the 2008 notiﬁcation, the 2011 FDA Safety Communication stated that 
complications “are NOT rare” and that “transvaginally placed mesh 
in POP repairs does NOT conclusively improve clinical outcomes over 
traditional non-mesh repairs” (21).  The Safety Communication aimed 
to educate the public and health care providers with adverse events 
relating to these devices and provided recommendations for informed 
decision-making regarding transvaginal mesh (21). In September 2011, 
an advisory panel of experts assembled for an open public hearing 
and presentations by both industry and the FDA to address questions 
regarding mesh safety for urogynecological applications for POP and 
SUI (21).  Regarding transvaginal placement of mesh, the advisory panel 
reached a number of consensus including the following: 
(i) The safety, efﬁcacy and beneﬁt ratio is not well established in 
transvaginal mesh. 
(ii) Improved premarket studies comparing mesh to non-mesh options 
need at least 1 year follow-up. 
(iii) Transvaginal meshes should be reclassiﬁed to Class III. 
(iv) Postmarket studies need to be ongoing.
(v) Mesh for abdominal sacrocolpopexy would not require reclassiﬁcation 
(21). Patients are encouraged to ask their surgeons several pertinent 
questions before proceeding with mesh placement (21). (See Table 1.1.) 
The advisory panel felt that the safety and efﬁcacy of retropubic and 
transobturator MUS is established, whereas single-incision mini slings 
FIGURE 1. VESICOVAGINAL FISTULAE
Figure 1. a) Patient presented with anterior vaginal midline mesh erosion and an associated vesicovaginal ﬁstula.  Site of mesh erosion was located near the left ureteric 
oriﬁce by cystoscopy. b) Surgical options for vesicovaginal ﬁstula involving an exposed mesh include transabdominal or transvaginal repairs.  Transabdominal repair of 
the vesicovaginal ﬁstula with removal of mesh was performed. The left ureteric orﬁce was in very close proximity to the ﬁstula and is depicted by the arrow, but was 
not reimplanted.  
a b
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require further investigation and should be used in study setting with 
long-term follow-up (21). More recently, Johnson & Johnson have 
withdrawn some of their mesh products from the global market (26). 
Although it is recommended that mesh and device complications are 
reported to the FDA through its MedWatch, the FDA Safety Information 
and Adverse Event Reporting program or respective national equivalent, 
surgeons and clinicians underreport adverse events as the reporting 
process can be time consuming and is completely voluntary (21).  Many 
acknowledge the need for a comprehensive registry of mesh use and 
outcomes (27-29).  Until such a national registry exists, recognition of 
device-associated complications will be further delayed until reported 
in the literature, thus exposing even more patients to these risks (28). 
Fortunately, a national registry of outcomes of mesh in incontinence 
and prolapse is underway in both Australia and the United Kingdom, 
initiated by their national urogynecological societies (30). The 
Urogynaecological Society of Australia (UGSA) database encourages its 
members to report their outcomes by offering the database at a low 
annual cost, giving CME credits for participating and arguing for the 
greater good since accurate surgical data will better support clinical and 
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TABLE 1.1. QUESTIONS BEFORE-AFTER SURGERY
Important questions patient should address with the surgeon preoperatively according to the FDA Safety Communication Update (July 12, 2011) are included in this 
table.  A summary of basic aspects of care following mesh surgery is included for the patient.
Modiﬁed from: FDA, Urogynecologic Surgical Mesh:  Update on the Safety and Effectiveness of Transvaginal Placement for Pelvic Organ Prolapse. July 2011.
regulatory decisions (30).  Companies marketing mesh products should 
be encouraged to employ code numbers and tracking systems to make 
identiﬁcation and follow-up of mesh easier. 
CLASSIFICATION OF MESH COMPLICATIONS
A classiﬁcation system of complications related directly to the insertion 
of prosthesis in female pelvic ﬂoor surgery has been instituted by both 
the International Urogynecological Association (IUGA) and International 
Continence Society (ICS) in efforts to standardize terminology for more 
precise reporting of complications which should help facilitate the 
implementation of a reliable registry (28, 31).  (See Table 2.1 for a list of 
the terminology.)  The classiﬁcation system coding is based on category 
of complication, time of clinical diagnosis and site of complication 
(31).  Pain is subclassiﬁed into 5 grades ranging from a (asymptomatic/
no pain) to e (spontaneous pain) (31).  Although a patient may suffer 
different complications at different times, all complications should be 
listed with the ﬁnal category for a single complication reported at its 
maximal score (31).  (See Table 2.2 for classiﬁcation.)
Before surgery After surgery
1. Are you planning to use mesh in my surgery?
2. Why do you think I am a good candidate for surgical mesh?
3. Why is surgical mesh being chosen for my repair?
4. What are the alternatives to transvaginal surgical mesh  repair for 
POP, including non-surgical options?
5. What are the pros and cons of mesh in my particular case?
6. How likely is it that my repair could be successfully performed 
without surgical mesh?
7. Will my partner be able to feel surgical mesh during sexual 
intercourse?
8. What if the surgical mesh erodes through my vaginal wall?
9. If surgical mesh is to be used, how often have you implanted this 
particular product? What results have your other patients had with 
this product?
10. What can I expect to feel after surgery and for how long?
11. Which speciﬁc side effects should I report to you after surgery?
12. What if the mesh surgery doesn’t correct my problem?
13. If I develop a complication, will you treat it or will I be referred to 
a specialist experienced with surgical mesh complications?
14. If I have a complication related to the mesh, how likely is it 
that the surgical mesh could be removed and what could be the 
consequences?
15. If a surgical mesh is to be used, is there patient information that 
comes with the product, and can I have a copy?
1. Continue routine follow-up care.
2. Notify health care provider if complications or symptoms:
    - Persistent vaginal bleeding or discharge
    - Pelvic or groin pain
    - Pain with sex
3. Let health care provides know if they have surgical mesh, 
especially if planning to have another related surgery or other 
medical procedures
4. Talk to health care provider about any questions or concerns.
5.  Ask the surgeon at her next check-up if she received mesh for 
POP surgery if she does not know if mesh was used. 
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TABLE 2.1. TERMINOLOGY INVOLVED FOR CLASSIFICATION
TERMS USED DEFINITIONS
PROSTHESIS A fabricated substitute to assist a damaged body part or to augment or stabilize a hypoplastic structure
a. MESH A (prosthetic) network of fabric or structure
b. IMPLANT A surgically inserted or embedded prosthesis
c. TAPE (SLING) A ﬂat strip of synthetic material
GRAFT Any tissue or organ for transplantation.  This term will refer to biological materials inserted
a. AUTOLOGOUS GRAFTS From the woman’s own tissues (e.g. dura mater, rectus sheath or fascia lata)
b. ALLOGRAFTS From post-mortem tissue banks
c. XENOGRAFTS From other species (e.g. modiﬁed porcine dermis, porcine small intestine, bovine pericardium)
COMPLICATION A morbid process or event that occurs during the course of a surgery that is not an essential part of that surgery
CONTRACTION Shrinkage or reduction of size
PROMINENCE Parts that protrude beyond the surface (e.g. due to wrinkling or folding with no epithelial separation)
SEPARATION Physically disconnected (e.g. vaginal epithelium)
EXPOSURE
A condition of displaying, revealing, exhibiting or making accessible (e.g. vaginal mesh visualized through separated 
vaginal epithelium)
EXTRUSION Passage gradually out of a body structure or tissue
COMPROMISE Bring into danger
PERFORATION Abnormal opening into a hollow organ or viscus
DEHISCENCE A bursting open or gaping along natural or sutured line
Terminology involved in the classiﬁcation of complications related directly to insertion of prosthesis (meshes, implants, tapes) or grafts in female pelvic ﬂoor surgery.
From: Haylen, B.T., Freeman, R.M., Swift, S.E. et al., IUGA/ICS Joint Terminology and Classiﬁcation of Complications Related Directly to the Insertion of Prosthesis 
(Meshes, Implants, Tapes) or Grafts in Female Pelvic Floor Surgery. 2012.
[REV. MED. CLIN. CONDES - 2013; 24(2) 229-237]
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IUGA/ICS classiﬁcation of complications related directly to insertion of prosthesis (meshes, implants, tapes) or grafts in female pelvic ﬂoor surgery.
From: Haylen, B.T., Freeman, R.M., Swift, S.E. et al., IUGA/ICS Joint Terminology and Classiﬁcation of Complications Related Directly to the Insertion of Prosthesis 
(Meshes, Implants, Tapes) or Grafts in Female Pelvic Floor Surgery. 2012.
TABLE 2.2. IUGA/ICS CLASSIFICATION OF COMPLICATIONS RELATED WITH DIRECTLY INSERTION OF PROSTHESIS
General Description A (Asymptomatic) B (Symptomatic) C (Infection) D (Abscess)
1. Vaginal:  No epithelial separation 
Include prominence (e.g. due to 
wrinkling or folding), mesh ﬁber 
palpation or contraction (shrinkage)
1A:  Abnormal prosthesis 
or graft ﬁnding on 
clinical exam
1B: Symptomatic e.g. 
unusual discomfort/
pain; dyspareunia (either 
partner); bleeding
1C: Infection (suspected 
or actual)
1D: Abscess
2. Vaginal: Smaller <1 cm exposure 2A: Asymptomatic 2B: Symptomatic 2C: Infection 2D: Abscess
3. Vaginal: Larger >1cm exposure, 
or any extrusion
3A: Asymptomatic
1-3Aa if no prosthesis or 
graft related pain
3B: Symptomatic
1-3B(b-e) if prosthesis or 
graft related pain
3C: Infection
1-3C(b-e) if prosthesis 
or graft related pain
4. Urinary tract: 
Compromise or perforation including 
prosthesis (graft) perforation, ﬁstula 
and calculus
4A:  Small intraoperative 
defect  
e.g. Bladder perforation
4B: Other lower urinary 
tract complication or 
urinary retention
4C: Ureteric or upper urinary tract complication
5. Rectal or Bowel: Compromise 
or perforation including prosthesis 
(graft) perforation and ﬁstula
5A: Small intraoperative 
defect (rectal or bowel)
5B: Rectal injury or 
compromise
5C: Small or large 
bowel injury or 
compromise
5D: Abscess
6. Skin and/or musculoskeletal: 
Complications including discharge, 
pain, lump or sinus tract formation
6A: Asymptomatic, 
abnormal ﬁnding on 
clinical exam
6B: Symptomatic eg. 
Discharge, pain or lump
6C: Infection e.g. Sinus 
tract formation
6D: Abscess
7. Patient: Compromise including 




7B: Major degrees of 







T1: Intraoperative- 48 hours T2: 48 hours – 2months T3: 2-12 months T4: Over 12 months
GRADES OF PAIN: SUBCLASSIFICATION OF COMPLICATION CATEGORY
a: Asymptomatic or no pain
b: Provoked pain only (during vaginal examination)
c: Pain during sexual intercourse 
d: Pain during physical activities
e: Spontaneous pain
SITE
S1: Vaginal: Area of suture line S2: Vaginal: Away from 
area of suture line
S3: Trocar passage
Exception: intra-abdominal (S5)




1-3D(b-e) if prosthesis 
or graft related pain
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FIGURE 2. 
Figure 2. a) Cystoscopic view of mesh extended at the right side of the bladder 
neck, covered with calciﬁcations 5 years after placement of a retropubic 
midurethral sling. b) Holmium laser (365 micron ﬁber) was used to eliminate 
as many mesh fragments as possible.  c) Cystoscopic view of completed laser 





As the long-term consequences of mesh are still unknown, patients 
with mesh placed for SUI and POP should have long-term (>10 
years) follow-up to monitor for complications or symptoms (32-34). 
Complications with mesh can occur several years later and the ﬁeld is 
becoming increasingly litigious (34, 35). Patients with mesh who do 
not have complications should not undergo mesh explantation (32). A 
detailed history should screen for vaginal discharge, vaginal bleeding, 
pelvic or groin pain, dyspareunia, hispareunia, UTIs, urinary urgency, 
incomplete emptying, prolonged or slow urinary stream as well as 
bowel complaints. Onset of the symptoms, type of mesh used preferably 
based on an operative report, prior pelvic surgeries, investigations and 
treatments should be attained.  A pelvic exam is necessary to assess for 
mesh exposure, prominence of scar tissue, recurrence of prolapse or SUI, 
and areas of tenderness or discomfort.  In severe cases, patients unable 
to tolerate the exam may require an examination under anesthesia. 
Cystourethroscopy can be useful to identify mesh exposed in the lower 
urinary tract (Figure 2) and distortion of the urethral lumen (Figure a). For 
voiding complaints, urodynamic studies and voiding cystourethrogram 
(VCUG) have been useful.  For bladder outlet obstruction following MUS 
placement, patients may demonstrate detrusor overactivity but more 
consistently will exhibit a prolonged or intermittent ﬂow curve with an 
elevated detrusor pressure on urodynamic testing (Figure b). Another 
ﬁnding of bladder obstruction secondary to MUS on VCUG is urethral 
narrowing and kinking at the level of the MUS with proximal urethral 
dilatation (Figure3c) (36).  Present imaging strategies with MRI and 
ultrasound are generally of limited use for pre-surgical planning, but 
sometimes identify the mesh.
Management Options:  
Vaginal extrusions and exposure may be managed conservatively if 
exposure is < 1cm and not associated with any complicating factors 
(23, 37).  Local estrogen therapy is often employed but the literature 
reﬂects mixed results (23, 38).  If vaginal extrusion/exposure is larger 
or fails to heal satisfactorily with conservative measures, mesh excision 
should be considered (23, 29, 37, 38). Often a limited excision of mesh 
is attempted under local anesthesia in cases of small persistent areas 
of vaginal mesh exposure (29, 38). Management of mesh involving 
the urinary tract has been reported with excision via either the vaginal 
or abdominal approaches, endoscopically with ablation with holmium 
laser or transurethral resection with electrocautery (39, 40). Combined 
laparoscopic and endoscopic procedures have also been described 
(41).
For urinary retention following placement of a suburethral tape 
that persists for > 1 week, loosening the sling or sling incision is 
recommended. Despite a prior sling incision at another institution, 
we caution the reader about some patients who continue to have 
obstructive symptoms and clinical evidence of obstruction on 
urodynamics and VCUG, and may ultimately require excision of the 
tape and/or urethrolysis. It is likely that the longer the obstruction goes 
untreated, prolonged compression and ischemia of the midurethra can 
result in permanent scarring of the urethral lumen and consequential 
voiding dysfunction and bladder remodeling (42).  Behavioral therapy 
and anticholinergics have been reported for de novo detrusor 
overactivity following sling placement. Urgency symptoms frequently 
occur as a result of BOO; and thus BOO be excluded for any de novo 
symptoms after a sling procedure (43-45). In this case, tape excision to 
relieve the obstruction would be necessary.   
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Figure 3. Persistent lower urinary tract symptoms (frequency, urgency and mixed 
urinary incontinence), recurrent UTIS and incomplete emptying in a 50 year 
old woman who underwent a “loosening of her tape” at 3 months post-op. 
Cystoscopy revealed no exposed tape to explain her UTIs, but a very narrow lumen 
with elevation and ﬂattening of urethral ﬂoor depicted by the arrow in Figure 3a. 
Urodynamics (3b) and voiding cystogram conﬁrmed obstruction and its site (arrow 
on 3c).  Tape loosening or incision does not always release an obstruction completely 
and persistent symptomatology should raise the concern for residual obstruction.   
Figure 4. (Images modiﬁed from Dillon B, Gurbuz C, Zimmern P.  Long term results 
after complication of “prophylactic” suburethral tape placement.  Can J Urol. 2012; 
19:6424-30.) a) MUS placed underneath the urethra should be tension free but 
can result in urethral kinking and distortion.  It is preferable to incise the tape on 
the side of the urethra (marked by *) to reduce risk of urethral injury.   b) Tape 
is carefully peeled away from underneath the urethra. c) After midurethral tape 
excision, urethroscopy helps conﬁrm no urethral injury and documents restoration 






In some patients, either complete or partial removal of the mesh is the 
only effective treatment modality.  Mesh removal can be performed 
transvaginally or in a combined abdominal-vaginal approach.  Mesh 
removal is challenging as visualization is often limited and extent of 
tissue damage from the mesh is often unknown.  Success of mesh 
removal often depends on surgical experience in dealing with these 
complications. As a result, many patients travel great distances 
to tertiary referral centers to deal with their mesh complication as 
a last resort (42).  Tape excision technique is depicted in Figure 4 
(46). Speciﬁc complications following tape removal include recurrent 
incontinence, urethral stricture, persistent pain, bladder neck injury, 
vesicovaginal ﬁstula and need for repeat surgery. Complications 
following removal of transvaginal mesh are related to the affected 
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